Hutchmed (China) Limited

Transaction in Own Shares • Dec 29, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2826K

Hutchison China Meditech Limited

29 December 2015

Blocklisting Six Monthly Return

London: Tuesday, 29 December 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) announces the following blocklisting six monthly return:

1.	Name of applicant:		Hutchison China MediTech Limited
2.	Name of scheme:		Hutchison China MediTech Limited Share Option Scheme
3.	Period of return:		From 29 June 2015 to 28 December 2015
4.	Balance under scheme from previous return:		472,763 ordinary shares of US$1 each
5.	The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:		Nil
6.	Number of securities issued/allotted under scheme during period:		18,750 ordinary shares of US$1 each
7.	Balance under scheme not yet issued/allotted at end of the period:		454,013 ordinary shares of US$1 each
8.	Number and class of securities originally listed and the date of admission:		2,560,606 ordinary shares of US$1 each admitted on 26 June 2007
9.	Total number of securities in issue at the end of the period:		56,533,118 ordinary shares of US$1 each
Name of contact:			Christian Hogg
Address of contact:			21/F., Hutchison House, 10 Harcourt Road, Hong Kong
Telephone number of contact:			+852 2121 8200

Ends

Enquiries

Chi-Med Christian Hogg, CEO	Telephone:      +852 2121 8200
Panmure Gordon (UK) Limited	Telephone:      +44 20 7886 2500
Richard Gray Andrew Potts
Citigate Dewe Rogerson Anthony Carlisle David Dible	Telephone:      +44 20 7638 9571 Mobile:             +44 7973 611 888 Mobile:             +44 7967 566 919

Notes to Editors

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.  Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLRUKABRVAAUURA